Akebia Therapeutics (NASDAQ:AKBA) reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its ...
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the ...
The hyperphosphatemia market is projected to witness steady growth, driven by the increasing global prevalence of chronic kidney disease, diabetes, ...
Get the latest news and real-time alerts from Akebia Therapeutics, Inc. (AKBA) stock at Seeking Alpha.
Replay the call for the latest insights. Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results